Effect of feed restriction on hepatic estradiol metabolism and liver function in cows

Mamiko ONO, Tadatoshi OHTAKI, Toru NAKAHASHI and Shigehisa TSUMAGARI

1) Laboratory of Large Animal Clinical Sciences, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, 252-0880, Japan
2) Laboratory of Theriogenology, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, 252-0880, Japan

Correspondence to: Ono, M. Laboratory of Large Animal Clinical Sciences, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, 252-0880, Japan.
E-mail: oono.mamiko@nihon-u.ac.jp

Running head: METABOLISM OF FEED-RESTRICTED COWS
ABSTRACT

In this study, the effects of restriction feeding on the liver function, hepatic uridine diphosphate glucuronosyltransferase (UGT) activity, hepatic insulin-like growth factor (IGF)-1 mRNA expression and response to high-dose estradiol-17β (E2) administration were investigated in non-lactating cows. Cows were assigned to either restricted feeding (30% of total digestible nutrient requirement) or ad libitum feeding of a dent corn-based concentrate and roughage for a 2-week feeding trial (Day 1 = day of beginning the feeding trial). On day 14, a high-dose E2 administration study was carried out to examine plasma E2 levels as an indicator of hepatic E2 metabolism. Plasma E2 concentration in the restricted feeding group was consistently higher after high-dose E2 administration than in the control group. In addition, indocyanine green half-life value was prolonged by restricted feeding for 13 days, and increased liver triglyceride concentration and decreased liver UGT activity were caused by this restriction over 14 days. Restricted feeding did not affect plasma IGF-1 concentration or hepatic IGF-1 mRNA expression. These results suggest that two weeks of restriction feeding led to accumulation of triglyceride, decreased liver blood flow, and slightly impaired liver function, which in turn slowed down the hepatic metabolism of E2 without significantly impacting hepatic IGF-1 production.

KEY WORDS: dry cow, estrogen metabolism, insulin-like growth factor (IGF)-1, restricted feeding, uridine diphosphate glucuronosyltransferase (UGT) activity
INTRODUCTION

Sex steroid hormones are synthesized in the gonads and undergo metabolic transformations in the liver before being excreted into the urine and feces, except for a small fraction that is metabolized in the kidneys and intestine [3, 6]. The hepatic metabolism of these hormones has been studied in domestic animals. Parr et al. [13] found that the peripheral plasma progesterone (P₄) concentration is significantly influenced by the metabolic clearance rate in the liver of sheep. P₄ concentration is also directly affected by postprandial blood flow from the gut to the liver in ovariectomized ewes [14]. Wieghart et al. [18] investigated the role of digestible energy intake in portal and hepatic vein blood flow rates, and their data showed that these blood flow rates decreased in dairy cows on high-concentrate and high-forage diets with restricted intake. Wiltbank et al. [20] found that, compared to non-lactating cows, lactating cows on high dry-matter intake had higher liver blood flow and 2.3 times greater hepatic metabolic rates of P₄ and estrogen, resulting in lower circulating estrogen and P₄ concentrations. This, they proposed, could lead to poor reproductive performance in the form of lower conception rates, pregnancy loss, multiple ovulation, or diminished signs of estrus. Collectively, these findings indicate the important role of feed intake in hepatic metabolism of sex hormones through its effect on liver blood flow. However, few studies are available regarding this theory for dairy cows. An in vitro assay has been established for the measurement of estradiol-17β (E₂) glucuronidation activity by uridine diphosphate glucuronosyltransferase (UGT) using liver biopsy samples from dairy cows [4], but the level of UGT activity and its effect on circulating estrogen are not yet understood.
Insulin-like growth factor (IGF)-1 is produced mainly by the liver and greatly influenced by nutrition. In situations of high nutrient demand, such as during negative energy balance (NEB), the circulating IGF-1 concentrations are low. NEB partially controls the synthesis and secretion of IGF-1 from the liver [21]. In this study, we investigated the effect of two week-restriction feeding on hepatic estrogen metabolism (i.e. UGT activity), peripheral plasma insulin-like growth factor (IGF)-1 concentration, and hepatic IGF-1 mRNA expression.

MATERIALS AND METHODS

Animals

Eight non-pregnant, dry Holstein cows (parity range, 1-5; 8.6 ± 1.0 years of age; average body weight, 675.0 ± 26.8 kg) kept at the Department of Veterinary Medicine, Nihon University were used for the study. The cows were tied in a stall during the study period and fed with dent corn silage, oats, beet pulp, and dicalcium phosphate according to the Japanese Feeding Standard for dairy cattle [7]. All procedures used in this experiment were approved by the Ethical Committee for Animal Experimentation at the College of Bioresource Sciences, Nihon University (NUBSV-157).

Treatment

Cows were allocated to a control group (n=4) and restricted feeding group (n=4). In the restricted feeding group, cows were on restricted feeding for two weeks from Day 1 to Day 14 according to Rhoads et al. [16] with modification. Briefly, the restricted feeding cows were fed 30% of the total digestible nutrient (TDN) requirement and 25%
of dry matter intake (DM) with separate feeding, and control cows were fed 120% of TDN requirement and 100% of DM with separate feeding. In all cows, feed was supplied twice a day at 9:00 and 15:00, and water was given *ad libitum*.

To synchronize the estrous cycle, all cows received 100 μg of gonadotropin-releasing hormone (GnRH, fertirelin acetate; Concela®, MSD Animal Health, Tokyo, Japan) intramuscularly and insertion of a controlled intravaginal drug-releasing device (CIDR, containing 1.9 g of P₄; EAZI-BREED™ CIDR®, Livestock Improvement Association of Japan, Tokyo, Japan) into the vagina on Day 6. Seven days later, the CIDR was removed and 25 mg of prostaglandin F₂α (PGF₂α, dinoprost, Pronalgon® F, Zoetis, Parsippany, NJ, U.S.A.) was administered intramuscularly. Then, a high-dose E₂ administration study was performed at 2 days after CIDR removal and PGF₂α administration.

Body weight and body condition score (BCS) were measured every 2 days during the study period. Body weight was measured with an electronic scale (TRU-TEST EW5, Fujihira Industry, Tokyo, Japan), and BCS was measured according to Ferguson *et al.* [1].

**High-dose E₂ administration study**

High-dose E₂ administration was carried out on Day 14 prior to feeding, as described by Sangsritavong *et al.* [17] with minor modification. Briefly, E₂ (β-Estradiol, Sigma-Aldrich, St. Louis, MO, U.S.A.) was dissolved in 99.8% absolute ethanol (Wako Pure Chemical, Osaka, Japan) and diluted with physiological saline (Nippon Zenyaku Kogyo, Fukushima, Japan) to make a solution containing 3 μg/ml (w/v) E₂ and 1% ethanol. A 14-G catheter (Nippon Zenyaku Kogyo) was placed into both jugular veins,
connected with a butterfly needle, and flushed with physiological saline containing 25 IU/ml heparin. After an intravenous bolus injection of 10 mg of E₂ in 5 ml of 99.8% absolute ethanol, continuous infusion of 3 µg/ml (w/v) E₂ and 1% ethanol solution was administered at a rate of 10 ml/min for 7.5 hr. Cows were fed 3 hr after the bolus injection, at which time the blood E₂ concentration reaches the steady state, and the continuous infusion continued for another 4.5 hr after feeding. Blood samples were taken via contralateral catheter before E₂ administration and at 1-hr intervals after the start of E₂ infusion for 7.5 hr. The catheter was flushed with heparinized saline after each sampling. Blood samples were collected into heparinized vacuum tubes and centrifuged at 1,700 × g at 4 °C for 15 min to separate plasma, which was then stored frozen at -20 °C until E₂ assay.

**Blood sampling**

Blood was also sampled from the coccygeal vein from Day 1 to Day 14 before morning feeding (8:00). Samples were collected into vacuum tubes with glass granules coated with a clot activator for serum collection, and into heparinized vacuum tubes for plasma collection. Serum separator tubes were left to clot, and plasma separator tubes were placed in a cooler box. Tubes were then centrifuged at 1,700 × g at 4 °C for 15 min, and serum and plasma samples were stored frozen at -20 °C until assay.

**Liver biopsy**

Liver biopsy was performed according to the method described by Nitanai et al. [8] after blood sampling on Day 14. About 1.0 g of tissue was collected, immediately washed with sterile saline, and stored in liquid nitrogen until RNA extraction and UGT
and triglyceride (TG) assays.

**Indocyanine green (ICG) clearance**

An ICG clearance test was performed on Day 13 before morning feeding, and the ICG half-life ($T_{1/2}$) value was determined according to the method described by Ono et al. [11].

**Hormone assay**

Plasma P₄ concentrations were determined by enzyme immunoassay after diethylether extraction as described by Ono et al. [10]. The sensitivity of the assay was 0.16 ng/ml, and the intra- and inter-assay CVs were 6.0% and 9.5%, respectively. Plasma E₂ concentrations were determined by a time-resolved fluorescent immunoassay after diethylether extraction as described by Ono et al. [10]. The sensitivity of the assay was 0.80 pg/ml, and the intra- and inter-assay CVs were 5.0% and 10.7%, respectively. Plasma IGF-1 concentration was determined using a commercial enzyme-linked immunosorbent assay kit (Human IGF-I Quantikine ELISA Kit, R&D systems, Minneapolis, MN, U.S.A.). The sensitivity of the assay was 2 ng/ml, and the intra- and inter-assay CVs were 1.1% and 2.1%, respectively.

**Serum chemistry**

Serum samples were submitted to the Health Sciences Research Institute (Kanagawa, Japan) for aspartate transaminase (AST), γ-glutamyl transpeptidase (γ-GTP), total bilirubin (T-Bil), total cholesterol (T-Chol), non-esterified fatty acids (NEFA), glucose (Glu), and TG analysis.
IGF-1 mRNA expression analysis

Total RNA was extracted from liver tissue samples using Invitrogen’s TRIZOL Reagent (Thermo Fisher Scientific, Waltham, MA, U.S.A.). RNA concentration was determined by spectrophotometer (NanoDrop 1000, Thermo Fisher Scientific). RNA extracts were stored at -80 °C until processed for cDNA synthesis.

RNA extracts were incubated with 2 µl of recombinant DNase I (RNase-free, Takara Bio, Shiga, Japan) and 0.5 µl of recombinant ribonuclease inhibitor (RNaseOUT, Takara Bio) in 10 µl of 10× DNase Buffer (RNase-free, Takara Bio) for 30 min at 37 °C in a thermal cycler (MyiQ System, Bio-Rad, Hercules, CA, U.S.A.). cDNA synthesis was carried out on 500 ng of total RNA per sample using an Applied Biosystems High-Capacity RNA-to-cDNA kit (Thermo Fisher Scientific) with the following cycling program: 5 min at 25 °C (Step 1); 30 min at 42 °C (Step 2); 5 min at 85 °C (Step 3), and hold at 4 °C (Step 4).

Real-time PCR was performed using an Applied Biosystems 7500 Real-Time PCR System with a reaction mixture consisting of 25 µl of TaqMan Universal PCR Master Mix II, 1.25 µl of bovine IGF-1 probe (Bt03252280_m1, 5 pmol/µl, TaqMan Gene Expression Assay), 1.25 µl of 18S ribosomal RNA probe (TaqMan Eukaryotic 18S rRNA Endogenous Control, VIC/MGB probe) (all from Thermo Fisher Scientific), 17.5 µl of RNase-free water, and 25 ng of cDNA. All PCR reactions were carried out in triplicate. As a negative control, RNase-free water was used instead of cDNA. 18S ribosomal RNA was assayed as a housekeeping gene.

The relative threshold cycle (Ct) method was used for the quantification of RNA expression. Sample Ct values were normalized using the mean Ct value of
housekeeping gene mRNA (ΔCt = Sample Ct – Ct of endogenous control). Three liver samples were processed per animal, and the mean relative expression of IGF-1 mRNA value was calculated.

Hepatic UGT activity assay

Microsome fractions were prepared as described by Kadokawa et al. [4], and UGT activity was determined using a UGT-Glo Assay (Promega, Madison, WI, U.S.A.). Microsomal membrane proteins were solubilized by incubating 25 µg/ml microsomes in TES (pH 7.5) containing 0.01% cholic acid and 40 mM MgCl2 for 30 min on ice. The reaction was carried out for 30 min in Costar plates for fluorescent assay (Corning, NY, U.S.A.) with 20 µM substrate, according to the kit protocol. A Wallac 1420 Multilabel Counter (Perkin Elmer, Waltham, MA, U.S.A.) was used to conduct the assay. UGT activity is expressed as % substrate consumption after 30 min of reaction.

Hepatic TG concentration

An Adipogenesis Colorimetric/Fluorometric Assay Kit (BioVision, Milpitas, CA, U.S.A.) was used on weighed liver samples. The intra-assay and inter-assay variations were 3.1% and 6.3%, respectively.

Statistical analysis

StatView 5.0 (SAS Institute Japan, Tokyo) was used to examine differences between the two groups, and the Mann-Whitney U test was used to compare them. Repeated measures analysis of variance was used to compare changes in plasma P4 concentration during synchronization. Serum chemical values were compared in the groups between
Day 1 and Day 14 using a paired \( t \)-test. Correlation between hepatic TG concentration and UGT activity was analyzed by Spearman’s rank correlation coefficient. In the high-dose E\(_2\) administration study, the E\(_2\) concentration in one of the cows in the control group was higher than that in the other control individuals, and because it was rejected by the Grubbs-Smirnov rejection test, the mean value for the control group is shown as means ± standard error of the mean (SEM) of three cows. All data are expressed as means ± SEM. A level of 5% was considered significant.

RESULTS

**Body weight and BCS**

The body weight change rate was lower in the restricted feeding group than that in the control group from Day 2 to Day 14 (\( P < 0.05 \)) (Fig. 1). The mean body weight decreased by 87.3 kg after 14 days of the restriction diet. The body weight of the control group did not change during the study period.

Similarly, the BCS change rate in the restricted feeding group was lower than that in the control group from Day 7 to Day 14 (\( P < 0.05 \)) (Fig. 2). In restricted feeding group, the mean BCS on Day 14 was 0.312 points lower compared to that on Day 1. There was no change in BCS in the control group.

**Plasma E\(_2\) concentration**

Fig. 3 shows mean plasma E\(_2\) concentrations after high-dose E\(_2\) administration on Day 14. The plasma E\(_2\) concentration in the restricted feeding group remained higher than that in the control group during E\(_2\) infusion (\( P < 0.05 \)).
Plasma P₄ concentration

Plasma P₄ concentrations during the study period are shown in Fig. 4. Changes in P₄ concentrations were different between the two groups (P < 0.05).

Serum chemistry

Serum chemical values on Day 1 and Day 14 are shown in Table 1. No significant differences were observed in the control group between Day 1 and Day 14. In contrast, the restricted feeding group showed higher NEFA and T-Bil on Day 14 than those on Day 1 (P<0.05).

Liver function profiles

Liver function profiles are shown in Table 2. The ICG T₁/₂ value on Day 13 was longer in the restricted feeding group (10.5 ± 3.0 min) than in the control group (4.3 ± 0.4 min) (P < 0.05). The mean hepatic TG concentration on Day 14 was 63.3 ± 6.1 mg/g of wet weight in the restricted feeding group and was higher compared to 38.6 ± 7.4 mg/g of wet weight in the control group (P < 0.05). The hepatic UGT activity on Day 14 is shown in Fig. 5. After 2 weeks of restricted feeding, the hepatic UGT activity (12.9 ± 1.4%) was lower than that of the control group (20.4 ± 2.4%) (P < 0.05). The hepatic UGT activity was negatively correlated to the hepatic TG concentration (ρ = -0.905, P < 0.05) (Fig. 5).

The plasma IGF-1 concentration was 121.0 ± 21.5 ng/ml and 110.5 ± 7.5 ng/ml on Day 1 and 98.1 ± 16.7 ng/ml and 96.2 ± 8.7 ng/ml on Day 14 in the restricted feeding group and control group, respectively. No significant difference was found between the
groups. The hepatic IGF-1 mRNA expression was 1.8 ± 0.4 in the restricted feeding group and 1.8 ± 0.2 in the control group. These values were not significantly different.

DISCUSSION

In this study, we investigated the effect of restriction feeding on liver estrogen metabolism in non-lactating cows. Our results indicate that ICG t1/2 was prolonged by 30% TDN restricted feeding for 13 days, and increased liver TG concentration and decreased liver UGT activity were caused by this restriction over 14 days. As expected, the 2-week feeding restriction resulted in body weight reduction (87.3 kg) and BCS reduction (0.312 points). In our study, the plasma NEFA and T-Bil concentrations increased significantly over the 14 days of restriction feeding, indicating that lipomobilization had occurred. However, the restriction feeding did not cause altered serum chemistry values, indicating liver dysfunction or altered plasma IGF-1 and hepatic IGF-1 expression during the study period.

During the high-dose E2 administration, the restricted feeding group showed continuously higher E2 concentrations than the control group. These findings are consistent with a previous report on ovariectomized ewes [15], in which feeding restriction resulted in body weight reduction of 10 to 15% over 7 weeks and consistently higher serum E2 after high-dose E2 administration (0.31 µg/50 kg/hr) compared with ewes on a maintenance diet.

In wether lambs, energy restriction also results in decreased liver weight [19], which seems to precede body weight reduction [9]. It was also reported that hepatic metabolism of volatile fatty acids was decreased by 70% in dairy cows after six days of
fasting, and that even though the hepatic metabolic rate doubled after the reintroduction of feeding 3 days later, it remained 32% lower than that of pre-fasting levels [5]. We previously reported that the ICG t1/2 3 hr after feeding was shorter than the pre-feeding value, and that 4-day fasting prolonged ICG t1/2 in dry cows [11]. This finding suggests that ICG clearance is not only affected by impaired liver function, but also by gastrointestinal blood flow and hepatic blood flow due to the presence or absence of food intake. In the present study, high levels of serum NEFA and liver TG concentrations, and decreased hepatic UGT metabolism in the restricted group suggest a decreased metabolic capacity of the liver. However, since AST was in the normal range and the plasma IGF-1 concentration and hepatic IGF-1 mRNA expression level had not decreased, we concluded that the impairment of liver function was mild. This suggests that the prolonged ICG clearance time in the present study is caused by a slightly impaired liver function and a decrease in liver blood flow due to restricted feeding. Plasma E2 remained higher in the restricted feeding group after high-dose E2 administration, likely due to the decreased hepatic metabolism since 85% of E2 is metabolized in the liver [12].

We previously reported that in dry cows 4-day fasting leads to reduced hepatic steroid hormone metabolism through accumulation of fat in the liver, which causes high peripheral steroid hormone concentrations [10]. In contrast, in the current study, plasma P4 concentration was consistently lower in the restricted feeding group. This is probably because of poor development of the corpus luteum due to dietary restriction, as reported in heifers that were fed 62% of the TDN requirement [2]. However, it is also possible that P4 absorption from the intravaginally-placed CIDR was lower in these cows due to the reduced blood flow associated with restrictive feeding.
Together, the results presented in this report suggest that 2-week restricted feeding in dry dairy cows leads to the accumulation of TG and decreased liver blood flow, altering liver E2 metabolism by UGT without significantly impacting the synthesis and secretion of IGF-1.

REFERENCES


FIGURE LEGENDS

Fig. 1. Changes in body weight change rate during the study period. Cows were fed either a restricted feeding (n = 4; filled circle) or control diet (n = 4; open circle) for 14 days and received high-dose E2 administration on Day 14. Error bars indicate SEM. *, Significant difference between the two groups (P < 0.05).

Fig. 2. Changes in body condition score (BCS) change rate during the study period. Cows were fed either a restricted feeding (n = 4; filled circle) or control diet (n = 4; open circle) for 14 days and received high-dose E2 administration on Day 14. Error bars indicate SEM. *, Significant difference between the two groups (P < 0.05).

Fig. 3. Mean plasma estradiol-17β (E2) concentration on Day 14 during high-dose E2 administration. E2 infusion was started 3 hr before feeding and continued for another 4.5 hr post-feeding. Cows were fed either a restricted feeding (n = 4; filled circle) or control diet (n = 3; open circle) for 14 days before receiving high-dose E2 administration. Error bars, SEM. *, Significant difference between the two groups (P < 0.05).

Fig. 4. Changes in plasma progesterone (P4) concentration during the study period. Cows were fed either a restricted feeding (n = 4; filled circle) or control diet (n = 4; open circle) for 14 days and received high-dose E2 administration on Day 14. Error bars indicate SEM. E2, estradiol-17β; GnRH, gonadotropin-releasing hormone; PGF2α, prostaglandin F2α.
Fig. 5. Correlation between hepatic uridine diphosphate glucuronosyltransferase (UGT) activity and hepatic triglyceride (TG) concentration on Day 14. Cows were fed either a restricted feeding (n = 4; filled circle) or control diet (n = 4; open circle).
Table 1. Serum chemical values before (Day 1) and after the start of feeding trial (Day 14)

<table>
<thead>
<tr>
<th></th>
<th>Control (n = 4)</th>
<th>Restricted feeding (n = 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Day 1</td>
<td>Day 14</td>
</tr>
<tr>
<td>AST (IU/l)</td>
<td>52.5 ± 4.7</td>
<td>47.5 ± 6.8</td>
</tr>
<tr>
<td>γ-GTP (IU/l)</td>
<td>28.3 ± 1.9</td>
<td>27.3 ± 1.7</td>
</tr>
<tr>
<td>T-Bil (mg/dl)</td>
<td>0.2 ± 0.0</td>
<td>0.1 ± 0.0</td>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td>23.3 ± 3.7</td>
<td>13.8 ± 3.1</td>
</tr>
<tr>
<td>T-Chol (mg/dl)</td>
<td>88.0 ± 8.7</td>
<td>82.8 ± 7.6</td>
</tr>
<tr>
<td>NEFA (μEq/l)</td>
<td>225.0 ± 96.7</td>
<td>230.0 ± 89.8</td>
</tr>
<tr>
<td>Glu (mg/dl)</td>
<td>66.0 ± 1.6</td>
<td>71.0 ± 1.2</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SEM. Values with different letters (a, b) are significantly different (P < 0.05).

AST, aspartate transaminase; γ-GTP, γ-glutamyl transpeptidase; Glu, glucose; NEFA, non-esterified fatty acids; T-Bil, total bilirubin; T-Chol, total cholesterol; TG, triglyceride.
### Table 2. Comparison of liver function profiles

<table>
<thead>
<tr>
<th></th>
<th>Control (n = 4)</th>
<th>Restricted feeding (n = 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICG T$_{1/2}$ (min)</td>
<td>4.3 ± 0.4</td>
<td>a</td>
</tr>
<tr>
<td>Hepatic TG concentration (mg/g)</td>
<td>38.6 ± 7.4</td>
<td>a</td>
</tr>
<tr>
<td>Hepatic UGT activity (%)</td>
<td>20.4 ± 2.4</td>
<td>a</td>
</tr>
<tr>
<td>Plasma IGF-1 concentration (ng/ml)</td>
<td>96.2 ± 8.7</td>
<td>98.1 ± 16.7</td>
</tr>
<tr>
<td>Hepatic IGF-1 mRNA expression (arbitrary units)</td>
<td>1.8 ± 0.2</td>
<td>1.8 ± 0.2</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SEM.
Values with different letters (a, b) are significantly different (P < 0.05).
ICG, indocyanine green; TG, triglyceride; UGT, uridine diphosphate glucuronosyltransferase;
Fig 1
Fig 3
Fig 4